

# Dalvance - (500 mg/vial; Powder, Intravenous)

Generic Name	Dalbavancin Hydrochloride	Innovator	Abbvie
Dosage	500 mg/vial; Powder, Intravenous	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	DALVANCE is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Grampositive microorganisms.		
Complexities	Yes		

## **Chronology Of Events**

Please Contact contact@researchdelta.com to get Detailed Information.

## **Executive Summary**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

#### **Patent Status**

Please Contact contact@researchdelta.com to get Detailed Information.

# **Launch Timelines and Competition**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

# **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.